Healionics Expands Research Applications for STAR(TM) Biomaterial Scaffold and Announces Upcoming Conference Presentations.

Premiere Presentations at BIO 2008 International Convention and Investment in Innovation (IN3) Medical Device Summit

REDMOND, Wash. -- Healionics Corporation, a provider of tissue regeneration and device biointegration solutions to healthcare manufacturers, today announced that the Company has entered into multiple new research agreements for application of its STAR(TM) biomaterial. In addition, the Company announced premiere presentations at upcoming biotechnology and investment events: the BIO 2008 International Convention, June 17-20 in San Diego, Calif. and the Investment in Innovation (IN3) Medical Device Summit, June 17-19 in San Francisco, Calif.

The research agreements include six new partnerships that will evaluate STAR biomaterial in a range of applications including human aesthetics, obesity, diabetes, wound care, and infusion devices. Healionics' proprietary STAR - Sphere Templated Angiogenic Regeneration - is a biomaterial scaffold specifically engineered to enhance biointegration and promote healing of implanted medical devices. The agreements highlight the versatility of STAR biomaterial, which can be manufactured in precise formations and sizes to provide a tailored solution for new and existing device applications.

"We are pleased to be working with a diverse group of partners to evaluate the synergy of STAR in a variety of applications and look forward to continuing our outreach to future partners regarding the potential STAR may offer in improving the healing, biointegration and longevity of implantable devices and materials," said Robert Brown, Chief Executive Officer of Healionics.

Healionics recently opened a $6 million Series B financing round. The Company closed a Series A financing of $1.7 million in January of 2008. The financing will be used to support expansion of preclinical studies of STAR, develop additional applications with partners and refine and scale the STAR material manufacturing process.

Upcoming Conferences

Michel Alvarez, Chief Operating Officer, will give a presentation at the BIO Annual Convention on June 19 at 1:45 p.m. in Room 3. The Company will also exhibit in the Emerging Technologies area of the BIO 2008 exhibition at booth EC50.

Robert Brown, Chief Executive Officer, will give a company presentation at the IN3 Medical Device Summit, on June 18 during Track 3: High Growth Technologies.

About Healionics Corporation

Healionics is a privately held biomaterials company whose mission is to be the leading provider of tissue regeneration and device biointegration solutions to healthcare manufacturers. Their flagship STAR - Sphere Templated Angiogenic Regeneration - biomaterial scaffold is a paradigm shift in biocompatibility. Healionics Corporation is headquartered in Redmond, Washington. For more information, please visit http://www.healionics.com.